PIK3CA Mutation: Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 55-year-old woman with a history of infiltrating mixed ductal/lobular carcinoma. Originally posted on a forum in the ASCO Connection, users now have the opportunity to claim CME, completion, or participation certificates for completing this activity.

Learning Objectives:

  • Analyze treatment options for patients with ER+ metastatic breast cancer
  • Apply molecular testing options in patients with ER+ metastatic breast cancer
  • Evaluate the role of PIK3CA mutation in mediating resistance to endocrine therapy
  • Discuss the pathologist’s role in biomarker testing and molecular testing for metastatic breast cancer

This activity was made available on 3/26/2015 and will be reviewed on an annual basis to determine continued availability. A maximum of 1 AMA PRA Category 1 Credit ™ is available.

Competencies Addressed

Medical Knowledge (ACGME, AAPA)
Health Promotion, Health Protection, Disease Prevention, and Treatment (ONS)